A comparison of PD-1+CD8+ TIL and PD-1−CD8+ TIL expansion products in mouse solid tumor models (melanoma and colon cancer) and multiple myeloma models revealed that TSTs existed exclusively in PD-1+CD8+ TIL progeny and inhibited tumor progression. This evidence concerns the gene CD8A and plasma cell myeloma.